H. Lundbeck A/S - Product Pipeline Review - 2016

Published: Mar, 2016 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's, 'H. Lundbeck A/S - Product Pipeline Review - 2016', provides an overview of the H. Lundbeck A/S's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by H. Lundbeck A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of H. Lundbeck A/S
- The report provides overview of H. Lundbeck A/S including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses H. Lundbeck A/S's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features H. Lundbeck A/S's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate H. Lundbeck A/S's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for H. Lundbeck A/S
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding H. Lundbeck A/S's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
H. Lundbeck A/S Snapshot 6
H. Lundbeck A/S Overview 6
Key Information 6
Key Facts 6
H. Lundbeck A/S - Research and Development Overview 7
Key Therapeutic Areas 7
H. Lundbeck A/S - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
H. Lundbeck A/S - Pipeline Products Glance 15
H. Lundbeck A/S - Late Stage Pipeline Products 15
Filing rejected/Withdrawn Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
H. Lundbeck A/S - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
H. Lundbeck A/S - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
H. Lundbeck A/S - Drug Profiles 21
carbamazepine 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
idalopirdine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
LuAF-35700 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
nalmefene 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
vortioxetine hydrobromide 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
LuAF-11167 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
LUAF-20513 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
LUAF-64280 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
AF-40431 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules to Antagonize nAChR Alpha-4 Beta-2 for Brain Diseases 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules to Inhibit LRRK-2 for Parkinson's Disease 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
H. Lundbeck A/S - Pipeline Analysis 36
H. Lundbeck A/S - Pipeline Products by Target 36
H. Lundbeck A/S - Pipeline Products by Route of Administration 38
H. Lundbeck A/S - Pipeline Products by Molecule Type 39
H. Lundbeck A/S - Pipeline Products by Mechanism of Action 40
H. Lundbeck A/S - Recent Pipeline Updates 42
H. Lundbeck A/S - Dormant Projects 48
H. Lundbeck A/S - Discontinued Pipeline Products 49
Discontinued Pipeline Product Profiles 49
gaboxadol 49
LuAA-47070 49
idalopirdine 49
Lu-02750 50
Lu-35138 50
Lu-AA24493 50
LuAA-37096 50
LuAA-38466 50
LuAA-39959 50
LuAA-44608 51
LuAE-04621 51
ORE-10002 51
siramesine 51
tedatioxetine hydrobromide 51
vortioxetine hydrobromide 51
zicronapine 52
H. Lundbeck A/S - Company Statement 53
H. Lundbeck A/S - Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

H. Lundbeck A/S, Key Information 6
H. Lundbeck A/S, Key Facts 6
H. Lundbeck A/S - Pipeline by Indication, 2016 8
H. Lundbeck A/S - Pipeline by Stage of Development, 2016 9
H. Lundbeck A/S - Monotherapy Products in Pipeline, 2016 10
H. Lundbeck A/S - Partnered Products in Pipeline, 2016 11
H. Lundbeck A/S - Partnered Products/ Combination Treatment Modalities, 2016 12
H. Lundbeck A/S - Out-Licensed Products in Pipeline, 2016 13
H. Lundbeck A/S - Out-Licensed Products/ Combination Treatment Modalities, 2016 14
H. Lundbeck A/S - Filing rejected/Withdrawn, 2016 15
H. Lundbeck A/S - Phase III, 2016 16
H. Lundbeck A/S - Phase II, 2016 17
H. Lundbeck A/S - Phase I, 2016 18
H. Lundbeck A/S - Preclinical, 2016 19
H. Lundbeck A/S - Discovery, 2016 20
H. Lundbeck A/S - Pipeline by Target, 2016 36
H. Lundbeck A/S - Pipeline by Route of Administration, 2016 38
H. Lundbeck A/S - Pipeline by Molecule Type, 2016 39
H. Lundbeck A/S - Pipeline Products by Mechanism of Action, 2016 40
H. Lundbeck A/S - Recent Pipeline Updates, 2016 42
H. Lundbeck A/S - Dormant Developmental Projects,2016 48
H. Lundbeck A/S - Discontinued Pipeline Products, 2016 49
H. Lundbeck A/S, Subsidiaries 54